Select a community
ALS including PLS and PMA
Find out more about the PatientsLikeMe
ALS Community
Home > Community Treatment Reports > 5-Hydroxytryptophan (5-HTP) Treatment Report
What is 5-Hydroxytryptophan (5-HTP)?

5-Hydroxytryptophan or 5-HTP is a naturally-occurring amino acid marketed in the United States and other countries as a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Slow my ALS progress 5 1
Other 3 1
Constipation 1 0
General health 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
0 0%
Mild
0 0%
None
1 100%

Dosages

  daily 2 daily 300 mg weekly 100 daily 100 mg daily 200 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking 5-Hydroxytryptophan (5-HTP) (multiple reasons could be selected)
Reason # Patients Percentage of patients
Expense
1 33% Expense: 33%
Doctor's advice
1 33% Doctor's advice: 33%
Not indicated
1 33% Not indicated: 33%

See all 3 patients who’ve stopped taking 5-Hydroxytryptophan (5-HTP)

Currently Taking 5-Hydroxytryptophan (5-HTP)

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
1
1

Stopped Taking 5-Hydroxytryptophan (5-HTP)

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
1
1
0
1
0

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
1 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
1 100%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 23, 2009.